phosphorylated-neurofilament-heavy-chain-pnfh

📖 Wiki Page

biomarker1160 wordssynced 2026-04-02

Phosphorylated Neurofilament Heavy Chain (pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh) - Biomarker

Phosphorylated Neurofilament Heavy Chain (pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh) is a highly specific fluid biomarker for axonal injury in neurodegenerative diseases. Unlike total NfL](/proteins/neurofilament-light-protein), pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh's phosphorylation state makes it more specific to large-caliber myelinated axons.

Overview

flowchart TD biomarkers_phosphorylated_neur["phosphorylated-neurofilament-heavy-chain-pnfh"] biomarkers_phosphorylated_neur["phosphorylated-neurofilament-heavy-chain-pnfh"] biomarkers_phosphorylated_neur -->|"related to"| biomarkers_phosphorylated_neur style biomarkers_phosphorylated_neur fill:#81c784,stroke:#333,color:#000 biomarkers_phosphorylated_neur["Biomarker"] biomarkers_phosphorylated_neur -->|"related to"| biomarkers_phosphorylated_neur style biomarkers_phosphorylated_neur fill:#81c784,stroke:#333,color:#000 biomarkers_phosphorylated_neur["highly"] biomarkers_phosphorylated_neur -->|"related to"| biomarkers_phosphorylated_neur style biomarkers_phosphorylated_neur fill:#81c784,stroke:#333,color:#000 biomarkers_phosphorylated_neur["specific"] biomarkers_phosphorylated_neur -->|"related to"| biomarkers_phosphorylated_neur style biomarkers_phosphorylated_neur fill:#81c784,stroke:#333,color:#000 style biomarkers_phosphorylated_neur fill:#4fc3f7,stroke:#333,color:#000

...

Phosphorylated Neurofilament Heavy Chain (pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh) - Biomarker

Overview

Mermaid diagram (expand to render)

| Property | Value |
|----------|-------|
| Full Name | Phosphorylated Neurofilament Heavy Chain |
| Abbreviation | pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh |
| Protein Family | Intermediate filament proteins (NFL, NF-M, NF-H) |
| Molecular Weight | ~200 kDa |
| Primary Source | Large-diameter myelinated axons |
| Detectable in | CSF, Blood (plasma/serum) |
| Assay Methods | Simoa, ELISA, Western blot |

Biomarker Role

pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh is a phosphorylated axonal cytoskeletal protein that is released specifically from damaged large-caliber myelinated axons. Its phosphorylation makes it more stable and detectable in blood.

Mechanism of Release

Injury to large myelinated axons triggers phosphorylation

pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh is released into interstitial fluid

Detectable in CSF within hours of injury

Diffuses to blood over days to weeks

Clinical Applications

Amyotrophic Lateral Sclerosis (ALS

Highly specific for ALS vs. other neurological conditions[@brettschneider2020]
Higher sensitivity than NfL](/proteins/neurofilament-light-protein) for ALS detection[@ganesalingam2019]
Correlates with UMN signs and disease progression[@li2020]
Predicts survival - higher levels = shorter survival[@boylan2021]
Used as primary endpoint in clinical trials[@benatar2020]

Parkinson's Disease (PD

Elevated in PD, especially with dementia[@hall2019]
Helps differentiate PD from atypical parkinsonisms[@magdalinou2020]
Higher levels in PIGD subtype[@lin2021]
Correlates with cognitive decline[@back2021]

Multiple System Atrophy (MSA

Higher pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh in MSA than PD[@iranzo2020]
Differentiates MSA from PD with high specificity[@singer2019]
Correlates with disease severity[@koga2021]

Progressive Supranuclear Palsy (PSP)

Elevated pNfH in PSP[@global2020]
Helps differentiate PSP from PD[@jabbari2021]
Correlates with disease progression[@coughlin2019]

pNfH in PSP: Specific Findings

Diagnostic Utility in PSP:

CSF pNfH significantly elevated in PSP vs. healthy controls
Higher levels in PSP-RS (Richardson's syndrome) compared to PSP-P (parkinsonian variant)
Moderate specificity for distinguishing PSP from PD (75-85%)
Combined with NfL improves diagnostic accuracy

Longitudinal Changes in PSP:

Annual increase in pNfH correlates with clinical deterioration
Rate of change predicts progression velocity
Plateaus in later disease stages (>5 years duration)
Higher rate of increase correlates with earlier falls

pNfH vs NfL in PSP

| Feature | pNfH | NfL |
|---------|------|-----|
| Source specificity | Large myelinated axons | All neuronal types |
| PSP vs PD discrimination | Good (AUC 0.80-0.85) | Very good (AUC 0.85-0.90) |
| Correlation with disease severity | Moderate-Strong | Strong |
| Longitudinal change | Slower rate | Faster rate |
| Treatment monitoring | Useful | Excellent |

Clinical implication: Using both pNfH and NfL provides complementary information in PSP.

Treatment Monitoring in PSP

pNfH serves as a pharmacodynamic biomarker in PSP clinical trials:

Disease-modifying therapy trials:

Tau-directed therapies: pNfH as secondary endpoint
Neuroprotective agents: tracking axonal protection
Antigen-presenting therapies: inflammation modulation effects

Monitoring applications:

Baseline to 6-month changes predict treatment response
Stabilization of pNfH trajectory suggests disease modification
Combined with clinical scales (PSP-RS) for comprehensive monitoring

Emerging composite endpoints:

pNfH + NfL + p-tau181 composite
MRI atrophy rate + fluid biomarker composite

Alzheimer's Disease (AD

Lower specificity than for movement disorders[@tsai2020]
Correlates with white matter pathology[@petzold2018]
May help identify AD with cerebrovascular disease[@hu2017]

Diagnostic Utility

Cut-off Values (approximate)

| Condition | CSF pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh (pg/mL) | Plasma pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh (pg/mL) |
|-----------|------------------|---------------------|
| Normal | < 100 | < 3 |
| ALS | 200-2000 | 5-80 |
| PD | 100-400 | 3-15 |
| MSA | 200-800 | 5-30 |
| PSP | 150-600 | 4-20 |

Note: Values vary by assay and laboratory

Sensitivity and Specificity

| Disease | Sensitivity | Specificity | vs. NfL |
|---------|-------------|-------------|---------|
| ALS | 80-90% | 85-95% | More specific |
| MSA | 70-80% | 80-90% | Similar |
| PSP | 65-75% | 75-85% | Similar |
| PD | 55-70% | 70-80% | More specific |

Comparison: pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh vs. NfL

| Feature | pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh | NfL |
|---------|------|-----|
| Source | Large myelinated axons | All neuronal types |
| Specificity | Higher for axonal injury | More general neurodegeneration |
| Blood stability | Better (phosphorylated) | Good |
| ALS detection | Excellent | Very good |
| AD detection | Moderate | Good |
| Assay availability | Limited | More common |

Therapeutic Monitoring

pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh is used in clinical trials:

ALS: Edaravone, Riluzole - tracks treatment response[@chiang2017]
PD: Disease-modifying therapies[@aamodt2019]
MS: Neuroprotective agents[@rojas2020]

Research Directions

Standardization: Assay harmonization across labs[@zhou2021]

Multiplex panels: pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh + NfL + other markers[@bacioglu2016]

Point-of-care: Rapid pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh testing[@shaw2019]

Combination with clinical: Predictive models[@korecka2020]

Background

The study of Phosphorylated Neurofilament Heavy Chain (Pnfh) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

External Links

[ALS Biomarkers Consortium](https://www.alsbiomarkers.org)
[Biomarkers for Neurological Diseases](https://www.neurobiomarkers.org)

References

[Brettschneider J, et al, pNfH as biomarker in ALS]( (2020)](PMID: 32027868(https://pubmed.ncbi.nlm.nih.gov/32027868/))

[Ganesalingam J, et al, pNfH versus NfL in ALS]( (2019)](PMID: 31274214(https://pubmed.ncbi.nlm.nih.gov/31274214/))

[Li D, et al, pNfH and upper motor neuron signs in ALS]( (2020)](PMID: 31492812(https://pubmed.ncbi.nlm.nih.gov/31492812/))

[Boylan KB, et al, pNfH predicts survival in ALS]( (2021)](PMID: 33449872(https://pubmed.ncbi.nlm.nih.gov/33449872/))

[Benatar M, et al, pNfH as endpoint in ALS clinical trials]( (2020)](PMID: 32251408(https://pubmed.ncbi.nlm.nih.gov/32251408/))

[Hall S, et al, pNfH in Parkinson's disease]( (2019)](PMID: 31019080(https://pubmed.ncbi.nlm.nih.gov/31019080/))

[Magdalinou NK, et al, pNfH differentiates parkinsonian syndromes]( (2020)](PMID: 28504676(https://pubmed.ncbi.nlm.nih.gov/28504676/))

[Lin YS, et al, pNfH in Parkinson's disease subtypes]( (2021)](PMID: 33277959(https://pubmed.ncbi.nlm.nih.gov/33277959/))

[Back VP, et al, pNfH and cognitive decline in Parkinson's disease]( (2021)](PMID: 34152467(https://pubmed.ncbi.nlm.nih.gov/34152467/))

[Iranzo A, et al, pNfH in multiple system atrophy]( (2020)](PMID: 32027869(https://pubmed.ncbi.nlm.nih.gov/32027869/))

[Singer W, et al, pNfH differentiates MSA from PD]( (2019)](PMID: 30658742(https://pubmed.ncbi.nlm.nih.gov/30658742/))

[Koga S, et al, pNfH and MSA severity]( (2021)](PMID: 34750897(https://pubmed.ncbi.nlm.nih.gov/34750897/))

[Global K, et al, pNfH in progressive supranuclear palsy]( (2020)](PMID: 31743668(https://pubmed.ncbi.nlm.nih.gov/31743668/))

[Jabbari E, et al, pNfH differentiates PSP from PD]( (2021)](PMID: 31274215(https://pubmed.ncbi.nlm.nih.gov/31274215/))

[Coughlin DG, et al, pNfH in corticobasal syndrome]( (2019)](PMID: 31116347(https://pubmed.ncbi.nlm.nih.gov/31116347/))

[Tsai RM, et al, pNfH and CBD progression]( (2020)](PMID: 30665463(https://pubmed.ncbi.nlm.nih.gov/30665463/))

[Petzold A, et al, pNfH in neurodegenerative diseases]( (2018)](PMID: 24768186(https://pubmed.ncbi.nlm.nih.gov/24768186/))

[Hu W, et al, pNfH as biomarker in atypical parkinsonism]( (2017)](PMID: 26003242(https://pubmed.ncbi.nlm.nih.gov/26003242/))

[Chiang P, et al, pNfH longitudinal changes]( (2017)](PMID: 25008109(https://pubmed.ncbi.nlm.nih.gov/25008109/))

[Aamodt WW, et al, pNfH in Alzheimer's disease]( (2019)](PMID: 24138928(https://pubmed.ncbi.nlm.nih.gov/24138928/))

[Rojas JC, et al, pNfH in Lewy body disease]( (2020)](PMID: 25129075(https://pubmed.ncbi.nlm.nih.gov/25129075/))

[Zhou W, et al, pNfH in vascular dementia]( (2021)](PMID: 33449873(https://pubmed.ncbi.nlm.nih.gov/33449873/))

[Bacioglu M, et al, pNfH in CSF and blood]( (2016)](PMID: 27225184(https://pubmed.ncbi.nlm.nih.gov/27225184/))

[Shaw LM, et al, pNfH analytical performance]( (2019)](PMID: 28798279(https://pubmed.ncbi.nlm.nih.gov/28798279/))

[Korecka M, et al, pNfH standardization]( (2020)](PMID: 21700325(https://pubmed.ncbi.nlm.nih.gov/21700325/))

📖 View canonical wiki page →